Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

In regard to Shen et al.

Shao YH, Lu-Yao G.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):287. doi: 10.1016/j.ijrobp.2012.03.055. No abstract available.

PMID:
23312264
2.

In reply to Shao and Lu-Yao.

Shen X, Showalter TN.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):287-8. doi: 10.1016/j.ijrobp.2012.05.037. No abstract available.

PMID:
23312263
3.

Active Surveillance in Prostate Cancer: How Far Should We Go?

Saad F.

JAMA Oncol. 2015 Jun;1(3):340-1. doi: 10.1001/jamaoncol.2015.103. No abstract available.

PMID:
26181183
4.

Words of Wisdom. Re: Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-risk Prostate Cancer.

Gandaglia G, Briganti A, Montorsi F.

Eur Urol. 2016 Feb;69(2):370. doi: 10.1016/j.eururo.2015.10.059. No abstract available.

PMID:
26758517
5.

The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis.

Shen X, Keith SW, Mishra MV, Dicker AP, Showalter TN.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1154-9. doi: 10.1016/j.ijrobp.2011.09.055.

PMID:
22270175
6.

Prostate brachytherapy--the community hospital experience.

Percarpio B, Sanchez P, Kraus P, Corujo M, D'Addario P, Wolk J.

Conn Med. 2000 Sep;64(9):523-6.

PMID:
11055085
7.

Gold seed implantation in prostate brachytherapy.

Loening SA.

Semin Surg Oncol. 1997 Nov-Dec;13(6):419-24.

PMID:
9358588
8.

10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients.

Crook J, Borg J, Evans A, Toi A, Saibishkumar EP, Fung S, Ma C.

Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1323-9. doi: 10.1016/j.ijrobp.2010.04.038.

PMID:
20675072
9.

Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate.

Winkfield KM, Chen MH, Dosoretz DE, Salenius SA, Katin M, Ross R, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e345-50. doi: 10.1016/j.ijrobp.2011.02.022.

PMID:
21514066
10.

Loose seeds versus stranded seeds in I-125 prostate brachytherapy: differences in clinical outcome.

Hinnen KA, Moerland MA, Battermann JJ, van Roermund JG, Monninkhof EM, Jürgenliemk-Schulz IM, van Vulpen M.

Radiother Oncol. 2010 Jul;96(1):30-3. doi: 10.1016/j.radonc.2010.02.012.

PMID:
20215039
11.

Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy.

Fang LC, Dattoli M, Taira A, True L, Sorace R, Wallner K.

Urology. 2008 Jan;71(1):146-50. doi: 10.1016/j.urology.2007.08.024.

PMID:
18242384
12.

Improvement in prostate cancer survival over time: a 20-year analysis: the Will Rogers phenomenon returns.

Lee WR.

Cancer J. 2012 Jan-Feb;18(1):9-10. doi: 10.1097/PPO.0b013e31824672e1. No abstract available.

PMID:
22290250
14.

[Radiotherapy of prostatic carcinoma].

Jacobsen AB, Fosså SD, Odegaard A.

Tidsskr Nor Laegeforen. 1980 Jul 10;100(19-21):1230-3. Norwegian. No abstract available.

PMID:
7423453
15.
16.

Radiation therapy for prostatic cancer.

Flocks RH.

Urol Clin North Am. 1975 Feb;2(1):181-3. No abstract available.

PMID:
1128747
17.

Iodine 125 seed implants for prostatic carcinoma. Five- and ten-year follow-up.

Weyrich TP, Kandzari SJ, Jain PR.

Urology. 1993 Feb;41(2):122-6.

PMID:
8497980
19.

Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer.

Pinkawa M, Piroth MD, Holy R, Fischedick K, Schaar S, Borchers H, Heidenreich A, Eble MJ.

Radiother Oncol. 2010 Jul;96(1):25-9. doi: 10.1016/j.radonc.2010.02.010.

PMID:
20231039
Items per page

Supplemental Content

Support Center